Comparison of response to salmeterol/fluticasone combination (SFC) therapy in elderly- versus younger- onset asthma and COPD

INTERVENTION: Salmeterol/fluticasone propionate combination aerosol, 2 puff twice daily, for 12, 24 weeks in younger‐onset asthma Salmeterol/fluticasone propionate combination aerosol, 2 puff twice daily, for 12, 24 weeks in elderly‐onset asthma Salmeterol/fluticasone propionate combination aerosol, 2 puff twice daily, for 12, 24 weeks in COPD CONDITION: Bronchial asthma, COPD PRIMARY OUTCOME: Asthma control questionnaire (ACQ); Spirometry; exhaled nitric oxide; exacerbation; Asthma Control Test (ACT); COPD Assessment Test (CAT) SECONDARY OUTCOME: Relevance of changes in the primary ; Outcomes.; The following background factors at start of intervention. ; Age; Gender ; Height ; Weight ; Duration of disease ; Smoking history; Co morbidity; Blood test; Reversibility of airway.; Adverse events, serious adverse ; events, side effects, number and frequency of serious side effects. ; The percentage of discontinued patients(%) INCLUSION CRITERIA: Asthma: 1, At entry, patients with adult asthma developed within three years. Gender does not matter. 2, Adult patients with mild to moderate persistent asthma. 3, Patient developed in over 65 years registered as elderly‐onset asthma. 4, Patient developed in 40 years or less registered as young‐onset asthma. COPD: 1, Diagnosed with COPD, and unused inhaled corticosteroid. Gender does not matter. 2, Long term treatment with bronchodilator including long acting beta‐agonist. Common criteria: Patient was able to get a written consent from the person.